by rob@robmaguiredesigns.com | May 2, 2024 | Press Releases
BOSTON, Mass., May 2, 2024 – Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two...
by rob@robmaguiredesigns.com | Apr 2, 2024 | Press Releases
– Preclinical data supports potential for iGPS® particles to provide off-the-shelf in vivo CAR-T Cell therapies without need for lymphodepleting chemotherapy – BOSTON, Mass., April 2, 2024 – Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...
by rob@robmaguiredesigns.com | Mar 28, 2024 | Press Releases
– World-renowned leaders in cell therapy, drug discovery and development join Kelonia as it moves toward early clinical development of in vivo CAR-T cell therapies – BOSTON, Mass., March 28, 2024 – Kelonia Therapeutics, a biotech company revolutionizing in vivo...
by rob@robmaguiredesigns.com | Feb 15, 2024 | Press Releases
– Innovative universal, off-the-shelf in vivo CAR-T Cell therapy – TOKYO and BOSTON, Mass., February 15, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Kelonia Therapeutics (CEO, Founder: Kevin Friedman,...
by rob@robmaguiredesigns.com | May 17, 2023 | Press Releases
Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of All Multiple Myeloma Patients Preclinical data in mice and non-human primates demonstrate...
by rob@robmaguiredesigns.com | May 2, 2023 | Press Releases
Preclinical data demonstrate iGPS particles efficiently and specifically deliver CAR molecules to T cells in vivo for durable tumor clearance without need for lymphodepleting chemotherapy Company developing iGPS technology to provide potentially safe, efficacious,...